Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CMOP in newly diagnosed extranodal diffuse large B-cell lymphoma
ChiCTR2400083635Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, vindesine, pegylated liposomal doxorubicin and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Union Hospital. Primary endpoint: Complete remission rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
rituximabcyclophosphamidevindesinepegylated liposomal doxorubicinprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400083635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083635.